ERBB2 and breast carcinoma: Talazoparib is approved for the therapy of adult individuals diagnosed with locally advanced or metastatic breast cancer that is HER2-negative and is associated with deleterious or suspected deleterious germline mutations in the breast cancer susceptibility gene (BRCA) [149].